Evaluation of tumor efficacy is central to cancer care. Progression‐free survival (PFS) is widely used as an early surrogate for treatment effectiveness, but more timely and reliable biomarkers are needed.… Click to show full abstract
Evaluation of tumor efficacy is central to cancer care. Progression‐free survival (PFS) is widely used as an early surrogate for treatment effectiveness, but more timely and reliable biomarkers are needed. Early tumor shrinkage (ETS) and depth of response (DpR) have emerged as promising predictors: ETS reflects early treatment sensitivity at first radiologic assessment, whereas DpR quantifies the maximum tumor reduction and may capture the durability of benefit.
Keywords:
treatment;
response;
tumor shrinkage;
depth response;
tumor;
early tumor
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!